CPHA Canvax

"Among persons aged ≥50 years who reported homologous mRNA COVID-19 vaccination, injection site and systemic reactions were less frequent after a second booster dose than after the first booster dose. Ninety-five percent of 8,515 events reported to the Vaccine Adverse Event Reporting System were nonserious." - Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022 

Additional Authors: Phillip G. Blanc, John R. Su, Brandon Hugueley, Casey Parker, Tanya R. Myers, Julianne Gee, Tom T. Shimabukuro, David K. Shay

Rating See Comments Ratings


Vaccine Safety and Development,Vaccine Safety,Vaccine Safety,Adverse Events Following Immunization (AEFI),Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19,Specific Populations,Adults,Seniors Vaccine Safety and Development
Vaccine Safety
Vaccine Safety
Adverse Events Following Immunization (AEFI)
Monitoring and Surveillance
Outbreaks and Pandemics
Specific Populations


Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.